

Blood viscosity and its determinants in the highest city in the world

Emeric Stauffer^{1,2,3}, Emmanuelle Loyrion⁴, Ivan Hancco⁴, Xavier Waltz⁴, Mathilde Ulliel-Roche⁴, Laura Oberholzer⁵, Paul Robach^{4,6}, Aurélien Pichon⁷, Julien V. Brugniaux⁴, Pierre Bouzat⁴, Stéphane Doutreleau⁴, Philippe Connes^{1,2,8} and Samuel Verges⁴

Edited by: Harold Schultz & Frank Powell

Key points

- Highlanders develop unique adaptative mechanisms to chronic hypoxic exposure, including substantial haemoglobin and haematocrit increases.
- However, a significant proportion of populations living permanently at high altitude develop maladaptive features known as chronic mountain sickness (CMS).
- This study aimed to assess the effects of permanent life at high altitude on clinical and haemorheological parameters (blood viscosity and red blood cell aggregation) and to compare clinical and haemorheological parameters of dwellers from the highest city in the world according to CMS severity.
- Blood viscosity increased with altitude, together with haemoglobin concentration and haematocrit. At 5100 m, highlanders with moderate-to-severe CMS had higher blood viscosity mainly at high shear rate and even at corrected haematocrit (40%), with a lower red blood cell aggregation.
- Blood viscosity may contribute to CMS symptomatology but the increased blood viscosity in CMS patients cannot solely be explained by the rise in haematocrit.

Emeric Stauffer is currently a Hospital Practitioner at Lyon University Hospital (France) in the Centre for Sleep and Respiratory Disease and a PhD student in the Inter-university Laboratory of Human Movement Biology (LIBM EA7424) in the 'Biologie vasculaire et du globule rouge' Team; University Claude Bernard Lyon1 (France). He also holds a doctorate in medicine, university degrees in sport medicine and sleep medicine, and a master's degree in the science of 'integrated physiology in extreme conditions', all obtained at University Claude Bernard Lyon1 (France). His main interests are hypoxia, haemorheology, sickle cell disease and obstructive sleep apnoea.



¹Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team 'Biologie vasculaire et du globule rouge', Université Claude Bernard Lyon 1, Université de Lyon, France

²Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France

³Centre de Médecine du Sommeil et des Maladies Respiratoires, Hospices Civils de Lyon, Hôpital Croix Rousse, Lyon, France

⁴HP2 laboratory, Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Faculté de Médecine, Grenoble, 38000, France

⁵The Centre of Inflammation and Metabolism and the Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

⁶National School for Mountain Sports, Site of the National School for Skiing and Mountaineering (ENSA), Chamonix, France

⁷Laboratoire MOVE, Université de Poitiers, Poitiers, France

⁸Institut Universitaire de France, Paris, France